Five‐Grass‐Pollen Sublingual Immunotherapy Drops Are Efficacious and Well Tolerated in Adults: The RHAPSODY Phase III Trial
Authors:
Open Access
Abstract
Background: Tablet formulations of allergen extracts are widely recommended over other formulations for the sublingual immunotherapy (SLIT) of respiratory allergies. However, with adequate clinical trial evidence, SLIT (liquid) drop formulations may be a relevant allergy treatment option. Methods: The RHAPSODY multinational, Phase III, parallel‐group, double‐blind, placebo‐controlled, randomised clinical study of adults with moderate‐to‐severe, grass‐pollen‐induced allergic rhinoconjunctivitis (ARC) with or without asthma was conducted at 45 investigating centres in six European countries. Participants received 26 months of continuous treatment with active 5‐grass‐pollen SLIT drops or placebo. The primary efficacy endpoint was the average daily total combined score (TCS, comprising a symptom score and a rescue medication score) during the second peak grass pollen season (PGPS). Results: Of the 445 randomised patients (mean ± standard deviation (range) age: 32.6 ± 9.9 (18–63); males: 55.1%), 389 completed the trial. The primary efficacy endpoint showed a statistically significant difference in favour of active treatment versus placebo (average difference in the daily TCS: 1.88 (95% CI: 0.60–3.17); relative difference 26.51% (95% CI: 9.42–40.55); p = 0.0036). The difference (0.17 points) in the average weekly Rhinitis Quality of Life Questionnaire score during the second PGPS in favour of the active treatment was clinically relevant but not statistically significant. The differences in efficacy were generally driven by the medication score, rather than the symptom score. Most adverse events were mild and local. Conclusions: RHAPSODY was the first well‐powered clinical trial to show the positive risk–benefit ratio of 5‐grass‐pollen SLIT drops in adult participants with moderate‐to‐severe grass‐pollen‐induced ARC.Keywords
This publication has 42 references indexed in Scilit:
- Worldwide prevalence of rhinitis in adults: A review of definitions and temporal evolutionClinical and Translational Allergy, 2022
- Recent development on the use of sublingual immunotherapy tablets for allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2021
- The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseasesAllergology International, 2018
- Long-term effects of a house dust mite sublingual immunotherapy tablet in an environmental exposure chamber trialAnnals of Allergy, Asthma & Immunology, 2016
- Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analysesJournal of Allergy and Clinical Immunology, 2016
- Allergic RhinitisImmunology and Allergy Clinics of North America, 2016
- Variation of the group 5 grass pollen allergen content of airborne pollen in relation to geographic location and time in seasonJournal of Allergy and Clinical Immunology, 2015
- Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needsJournal of Allergy and Clinical Immunology, 2012
- Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tabletJournal of Allergy and Clinical Immunology, 2010
- Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: Case-control studyJournal of Allergy and Clinical Immunology, 2007